Artemether and imatinib combination therapy against malaria infection

Q4 Medicine

Infektsionnye Bolezni Pub Date : 2021-01-01 DOI:10.20953/1729-9225-2021-1-139-143

A. Kondrashin, E. Stepanova, L. Morozova, V. Sergiev, M. Maksimova, N. Turbabina, N. S. Malysheva, E. Solovyeva, I. V. Kurashkina, A. Dovgalev, E. Morozov

{"title":"Artemether and imatinib combination therapy against malaria infection","authors":"A. Kondrashin, E. Stepanova, L. Morozova, V. Sergiev, M. Maksimova, N. Turbabina, N. S. Malysheva, E. Solovyeva, I. V. Kurashkina, A. Dovgalev, E. Morozov","doi":"10.20953/1729-9225-2021-1-139-143","DOIUrl":null,"url":null,"abstract":"Artemisinin-based combination therapy (ACT) is recommended by the World Health Organization (WHO) as the first and second line of treatment for uncomplicated malaria caused by P. falciparum, as well as for chloroquine-resistant P. vivax malaria. Despite the large number of antimalarial drugs, there is no any ideal drug, since each individual combination of drugs or monotherapy have their own limitations, ranging from their triple (activity) in relation to certain forms of the development of Plasmodium in the human body, side effects, toxicity and resistance. During the course of the study carried out, the most promising compound-candidate was selected – imatinib, which is currently used as targeted therapy for a number of oncological diseases. The objective of this work is to evaluate the efficacy of the combined use of imatinib and artemether in vivo studies on the human malarial model – the rodent malaria parasites Plasmodium berghei. Dut to the optimally selected treatment scheme, it was possible to reduce the dosage of imatinib twice – to 0,25 mg/kg, and that of artemether three times – to 33 mg/kg. The use of this scheme made it possible to considerably reduce the toxic effect of these drugs due to the potentiation of antimalarial effect. Key words: malaria, drug resistance, telomerase inhibitors, imatinib, chemotherapy of malaria","PeriodicalId":37794,"journal":{"name":"Infektsionnye Bolezni","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Infektsionnye Bolezni","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.20953/1729-9225-2021-1-139-143","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Artemisinin-based combination therapy (ACT) is recommended by the World Health Organization (WHO) as the first and second line of treatment for uncomplicated malaria caused by P. falciparum, as well as for chloroquine-resistant P. vivax malaria. Despite the large number of antimalarial drugs, there is no any ideal drug, since each individual combination of drugs or monotherapy have their own limitations, ranging from their triple (activity) in relation to certain forms of the development of Plasmodium in the human body, side effects, toxicity and resistance. During the course of the study carried out, the most promising compound-candidate was selected – imatinib, which is currently used as targeted therapy for a number of oncological diseases. The objective of this work is to evaluate the efficacy of the combined use of imatinib and artemether in vivo studies on the human malarial model – the rodent malaria parasites Plasmodium berghei. Dut to the optimally selected treatment scheme, it was possible to reduce the dosage of imatinib twice – to 0,25 mg/kg, and that of artemether three times – to 33 mg/kg. The use of this scheme made it possible to considerably reduce the toxic effect of these drugs due to the potentiation of antimalarial effect. Key words: malaria, drug resistance, telomerase inhibitors, imatinib, chemotherapy of malaria

查看原文本刊更多论文

蒿甲醚和伊马替尼联合治疗疟疾感染

世界卫生组织(世卫组织)推荐以青蒿素为基础的联合疗法作为恶性疟原虫引起的无并发症疟疾以及耐氯喹间日疟原虫疟疾的一线和二线治疗方法。尽管抗疟药物数量众多，但没有任何理想的药物，因为每种药物组合或单一疗法都有其自身的局限性，包括与人体内某些形式的疟原虫发展有关的三重(活性)、副作用、毒性和耐药性。在进行研究的过程中，最有希望的候选化合物-伊马替尼被选中，它目前被用作许多肿瘤疾病的靶向治疗。本研究的目的是评估伊马替尼和蒿甲醚联合使用对人类疟疾模型——啮齿动物伯氏疟原虫的体内研究效果。根据最佳选择的治疗方案，有可能将伊马替尼的剂量减少两次至0.25 mg/kg，将蒿甲醚的剂量减少三次至33 mg/kg。使用这一方案可以大大减少这些药物的毒性作用，因为增强了抗疟作用。关键词:疟疾，耐药性，端粒酶抑制剂，伊马替尼，疟疾化疗

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Infektsionnye Bolezni Medicine-Infectious Diseases

CiteScore

1.30

自引率

0.00%

发文量

期刊介绍： The journal publishes original research works, reviews of literature, lectures, methodological recommendations, clinical observations. Main topics: problems of etiology, pathogenesis, clinical manifestations of infectious diseases, new techniques and methods of their diagnosis, prevention and treatment; special attention is paid to the problems of antibacterial and antiviral therapy, the use of immunoglobulins and interferons, and also to intensive therapy of critical states. The journal is in the List of leading scientific journals and periodicals of the Supreme Attestation Committee, where the principal results of doctoral dissertations should be published.